- NeuroScientific Biopharmaceuticals (NSB) reports positive results from off-target safety assessment of its lead drug candidate EmtinB
- EmtinB is a drug targeted at neurodegenerative conditions which affect the central nervous system such as Alzheimer’s and multiple sclerosis
- Of 173 biological targets, EmtinB did not interact with any targets known to cause major adverse reactions and toxicities in humans
- A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB in humans
- NeuroScientific Biopharmaceuticals Ltd (NSB) last traded at $30.5 cents per share before market open on December 24
NeuroScientific Biopharmaceuticals (NSB) reports positive results from the off-target safety assessment of its lead drug candidate EmtinB.
The assessment involves a comprehensive in vitro screening program to predict drug-induced toxicities in humans.
The preclinical in vitro screening program is undertaken by contract research company Eurofins CEREP in France.
Off-target safety assessments help to identify unintended interactions between a drug and a host of biological targets.
The International Conference on Harmonisation Guidance for Industry regulatory guidelines recommend the completion of off-target screening as part of risk mitigation strategies in planning for Phase I clinical studies.
EmtinB is a drug targeted at neurodegenerative conditions which affect the central nervous system such as Alzheimer’s and multiple sclerosis.
EmtinB is modelled on a specific active domain of the complex human protein, which is produced as part of the human body’s innate immune response to cell injury.
Preclinical research established EmtinB is highly specific and selective for its target receptor, safe and well-tolerated at high concentrations.
A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB in humans.
Of 173 biological targets screened, EmtinB did not interact with any known causes of human toxicities.
This demonstrates the low potential of EmtinB causing drug-induced adverse reactions or toxicities in humans.
Matt Liddelow, Neuro Scientific’s CEO, commented
“These positive safety results add further confidence to existing safety data for EmtinB™ in demonstrating its low liklihood to cause any major safety issues in humans and is another major step towards achieving the landmark milestone of starting first-in-human Phase I studies in the first half of 2022,” he said.
NeuroScientific is a company developing peptide-based pharmaceutical drugs that target several neurodegenerative conditions with high unmet medical demand.
NeuroScientific Biopharmaceuticals Ltd (NSB) last traded at $30.5 cents per share before market open on December 24.